Ardelyx, Inc. (ARDX)

Market Cap	1.24B
Revenue (ttm)	333.62M
Net Income (ttm)	-39.14M
Shares Out	238.36M
EPS (ttm)	-0.17
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,493,563
Open	5.23
Previous Close	5.25
Day's Range	5.03 - 5.27
52-Week Range	4.32 - 9.33
Beta	0.87
Analysts	Strong Buy
Price Target	10.61 (+104.24%)
Earnings Date	May 1, 2025

About ARDX

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 an...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 19, 2014
• Employees: 395
• Stock Exchange: NASDAQ
• Ticker Symbol: ARDX
• Website: https://www.ardelyx.com

Financial Performance

In 2024, Ardelyx's revenue was $333.62 million, an increase of 168.06% compared to the previous year's $124.46 million. Losses were -$39.14 million, -40.76% less than in 2023.

Analyst Forecast

According to 9 analysts, the average rating for ARDX stock is "Strong Buy." The 12-month stock price forecast is $10.61, which is an increase of 104.24% from the latest price.

Price Target

$10.61

(104.24% upside)

Analyst Consensus: Strong Buy